ロード中...
DIETARY SUPPLEMENT HYMECROMONE AND SORAFENIB: A NOVEL COMBINATION FOR THE CONTROL OF RENAL CELL CARCINOMA
PURPOSE: Current treatments for metastatic RCC (mRCC) do not extend survival beyond a few months. Sorafenib (SF) is a targeted drug approved for mRCC, but it has modest efficacy. Hymecromone is a nontoxic dietary supplement with some antitumor activity at high doses (450 – 3000 mg/day). HC inhibits...
保存先:
| 出版年: | J Urol |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5058418/ https://ncbi.nlm.nih.gov/pubmed/23228386 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.juro.2012.12.011 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|